Sanofi $SNY Shares Sold by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP reduced its holdings in Sanofi by 1.3%, ending the quarter with approximately 4.4 million shares worth around $245.5 million.
• Several hedge funds increased their stakes in Sanofi, including Bank of America with a 3.8% increase and Price T. Rowe Associates with an 88.5% increase in the most recent quarter.
• Sanofi reported earnings per share of $0.90 for the quarter, which fell short of analysts' expectations, despite a significant revenue surpassing estimates at $11.34 billion.

Wellington Management Group LLP lowered its holdings in Sanofi (NASDAQ:SNY - Free Report) by 1.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,427,436 shares of the company's stock after selling 56,882 shares during the period. Wellington Management Group LLP owned about 0.18% of Sanofi worth $245,546,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Bank of America Corp DE grew its stake in shares of Sanofi by 3.8% in the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock worth $579,587,000 after purchasing an additional 441,637 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Sanofi by 88.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after purchasing an additional 5,091,304 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Sanofi by 58.5% in the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock worth $218,933,000 after purchasing an additional 1,456,269 shares during the last quarter. Nuveen Asset Management LLC grew its stake in shares of Sanofi by 1.0% in the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock worth $177,304,000 after purchasing an additional 34,660 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in shares of Sanofi by 6.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company's stock worth $181,764,000 after purchasing an additional 211,641 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Barclays restated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research report on Monday, June 2nd. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Three investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $62.00.

Sanofi Price Performance

Shares of SNY opened at $50.19 on Wednesday. The company has a market capitalization of $123.24 billion, a price-to-earnings ratio of 12.06, a P/E/G ratio of 1.19 and a beta of 0.48. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The business's 50-day moving average is $48.57 and its 200-day moving average is $51.77.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi's revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.73 EPS. Equities research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.